- MyIllumina
- Tools
DNA Activation Kits are used in the first steps of the GoldenGate protocol to make biotin-labeled DNA that is then purified for use in the GoldenGate Assay amplification step. The DNA sample used in this assay is activated for binding to paramagnetic particles. This activation step requires a minimum input of DNA (250ng at 50ng/μl).
The GoldenGate Assay allows for a high degree of loci multiplexing during the extension and amplification steps, minimizing time, reagent volumes, and material requirements of the process.
- The DNA sample used in this assay is activated for binding to paramagnetic particles
- This activation step is a highly robust process that requires a minimum input of DNA (250ng at 50ng/μl. Depending upon the multiplex level, this equates to only 160pg of DNA per SNP genotype call
- Assay oligonucleotides, hybridization buffer, and paramagnetic particles are combined with the activated DNA in the hybridization step
Catalog IDs: GT-95-201, GT-95-202
View the product support page for additional technical information ยป
Innovative technologies
At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
© 2012 Illumina, Inc. All rights reserved.